UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.72% | -40.87% | -49.51% | -35.80% | -44.19% |
| Total Depreciation and Amortization | 121.90% | 140.23% | 126.62% | 41.60% | -27.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -45.08% | -0.99% | -44.60% | -20.03% | 60.41% |
| Change in Net Operating Assets | -209.87% | -54.73% | 111.66% | 50.90% | 105.06% |
| Cash from Operations | -181.41% | -52.80% | -67.70% | -32.42% | -4.79% |
| Capital Expenditure | 85.22% | 9.38% | -67.86% | -- | -105.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -54.34% | 129.52% | 136.28% | -291.74% | 638.06% |
| Cash from Investing | -54.28% | 129.41% | 136.76% | -292.06% | 634.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46,623.94% | -45.28% | -99.64% | -99.94% | 77.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -99.98% | -- | -- |
| Cash from Financing | 44,007.04% | -79.11% | -99.70% | -99.94% | 77.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -56.01% | 97.26% | -112.56% | -286.48% | 293.72% |